Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectiv...
Saved in:
Published in | Breast cancer research : BCR Vol. 12; no. 4; p. R47 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
01.01.2010
National Library of Medicine - MEDLINE Abstracts BioMed Central |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up.
Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score.
Increased Mammostrat scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P < 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P < 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 ± 1.5% in the low-risk group versus 20.0 ± 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients.
This is the fifth independent study providing evidence that Mammostrat can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer. |
---|---|
AbstractList | Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up. Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score. Increased Mammostrat scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P < 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P < 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 ± 1.5% in the low-risk group versus 20.0 ± 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients. This is the fifth independent study providing evidence that Mammostrat can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer. INTRODUCTION: Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up. METHODS: Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat® risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score. RESULTS: Increased Mammostrat® scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P < 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P < 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 ± 1.5% in the low-risk group versus 20.0 ± 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients. CONCLUSIONS: This is the fifth independent study providing evidence that Mammostrat® can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer. Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm.sup.2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat.sup.[R] risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score. Increased Mammostrat.sup.[R] scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P < 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P < 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 [+ or -] 1.5% in the low-risk group versus 20.0 [+ or -] 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients. This is the fifth independent study providing evidence that Mammostrat.sup.[R] can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer. Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up. Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score. Increased Mammostrat scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P < 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P < 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 ± 1.5% in the low-risk group versus 20.0 ± 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients. This is the fifth independent study providing evidence that Mammostrat can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer. Introduction Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat.sup.[R] test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up. Methods Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm.sup.2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat.sup.[R] risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score. Results Increased Mammostrat.sup.[R] scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P < 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P < 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 [+ or -] 1.5% in the low-risk group versus 20.0 [+ or -] 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients. Conclusions This is the fifth independent study providing evidence that Mammostrat.sup.[R] can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer. INTRODUCTIONPatients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up. METHODSTissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score. RESULTSIncreased Mammostrat scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P < 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P < 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 ± 1.5% in the low-risk group versus 20.0 ± 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients. CONCLUSIONSThis is the fifth independent study providing evidence that Mammostrat can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer. |
ArticleNumber | R47 |
Audience | Academic |
Author | Ross, Douglas T Munro, Alison Johnstone, Laura Campbell, Fiona M Kerr, Gillian R Chetty, Udi Thomas, Jeremy Cameron, David A Kunkler, Ian H Bartlett, John M S Ring, Brian Z Beck, Rodney A Jack, Wilma Seitz, Robert S Pedersen, Hans Christian |
AuthorAffiliation | 2 Edinburgh Cancer Centre, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, UK 3 Clarient Inc., 31 Columbia, Aliso Viejo, CA 92656, USA 1 Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Carrington Crescent, Edinburgh EH4 2XU, UK |
AuthorAffiliation_xml | – name: 1 Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Carrington Crescent, Edinburgh EH4 2XU, UK – name: 2 Edinburgh Cancer Centre, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, UK – name: 3 Clarient Inc., 31 Columbia, Aliso Viejo, CA 92656, USA |
Author_xml | – sequence: 1 givenname: John M S surname: Bartlett fullname: Bartlett, John M S email: john.bartlett@ed.ac.uk organization: Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Carrington Crescent, Edinburgh EH4 2XU, UK. john.bartlett@ed.ac.uk – sequence: 2 givenname: Jeremy surname: Thomas fullname: Thomas, Jeremy – sequence: 3 givenname: Douglas T surname: Ross fullname: Ross, Douglas T – sequence: 4 givenname: Robert S surname: Seitz fullname: Seitz, Robert S – sequence: 5 givenname: Brian Z surname: Ring fullname: Ring, Brian Z – sequence: 6 givenname: Rodney A surname: Beck fullname: Beck, Rodney A – sequence: 7 givenname: Hans Christian surname: Pedersen fullname: Pedersen, Hans Christian – sequence: 8 givenname: Alison surname: Munro fullname: Munro, Alison – sequence: 9 givenname: Ian H surname: Kunkler fullname: Kunkler, Ian H – sequence: 10 givenname: Fiona M surname: Campbell fullname: Campbell, Fiona M – sequence: 11 givenname: Wilma surname: Jack fullname: Jack, Wilma – sequence: 12 givenname: Gillian R surname: Kerr fullname: Kerr, Gillian R – sequence: 13 givenname: Laura surname: Johnstone fullname: Johnstone, Laura – sequence: 14 givenname: David A surname: Cameron fullname: Cameron, David A – sequence: 15 givenname: Udi surname: Chetty fullname: Chetty, Udi |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20615243$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kt9rFDEQx4NU7A_F_0CCPvh0bZLNj10fhFL8BS2-KPgWkuzsNXU3OZOscP-9ud5Z7qQSSIaZz3xnMswpOgoxAEIvKTmntJUX1iUmCX-CTiiXYiE4-3G0Zx-j05zvCKGqFe0zdMyIpILx5gQNN2aaYi7JFGwyNrjEONYL37v8sMY2gckFOxMcJLyqTgilkgUnn3_iOOAEbk4Jahz3c_JhiSH00VULcLmFZFbr5-jpYMYML3bvGfr-8cO3q8-L66-fvlxdXi-sIF1Z8FYJZ5irjUrqmOKWywZAOOYGBso62nHDuIPGckMYtV2rOi5IL1UPlKrmDL3f6q5mO0HvaqvJjHqV_GTSWkfj9WEk-Fu9jL8163gnG14F3m0FrI__ETiMuDjp3fRr8ttd9RR_zZCLnnx2MI4mQJyzVkJK2XaEVvL1P-RdnFOoo9lAigvORYXebKGlGUH7MMRa0W0k9SVviSSCdRvq_BGqnh4m7-qaDL76DxJ2XboUc04wPPyOEr3Zpr3_vNqf5gP3d32aP-UeyJQ |
CitedBy_id | crossref_primary_10_1016_j_clon_2012_10_005 crossref_primary_10_1074_jbc_RA118_002894 crossref_primary_10_1016_j_drup_2018_05_002 crossref_primary_10_3390_microarrays2030228 crossref_primary_10_1200_JCO_2012_44_6955 crossref_primary_10_3390_genes10010019 crossref_primary_10_4137_BIC_S9455 crossref_primary_10_2217_fon_15_204 crossref_primary_10_1016_j_biopha_2018_06_066 crossref_primary_10_1097_CCO_0000000000000252 crossref_primary_10_3390_ijms19030907 crossref_primary_10_1016_j_soncn_2015_02_008 crossref_primary_10_1002_ijc_30371 crossref_primary_10_1038_labinvest_2015_2 crossref_primary_10_1093_jnci_djs261 crossref_primary_10_1634_theoncologist_2012_0007 crossref_primary_10_3310_hta20100 crossref_primary_10_2217_fon_12_57 crossref_primary_10_1038_bjc_2014_156 crossref_primary_10_3390_ijms19082373 crossref_primary_10_3892_or_2021_8228 crossref_primary_10_1093_jnci_djw314 crossref_primary_10_1155_2011_373584 crossref_primary_10_1158_0008_5472_CAN_14_2258 crossref_primary_10_1186_s12918_015_0211_x crossref_primary_10_3389_fmed_2018_00248 crossref_primary_10_1016_j_jval_2013_03_1625 crossref_primary_10_1177_107327481502200213 crossref_primary_10_1186_s13059_015_0779_x crossref_primary_10_1002_jcb_29409 crossref_primary_10_1007_s12609_013_0125_9 crossref_primary_10_1186_bcr3642 crossref_primary_10_1016_j_molmed_2014_01_008 crossref_primary_10_1172_JCI137552 crossref_primary_10_1080_10520295_2017_1290276 crossref_primary_10_4103_2153_3539_137731 crossref_primary_10_18632_oncotarget_18692 crossref_primary_10_1186_s12864_015_1929_y crossref_primary_10_1089_dna_2011_1437 crossref_primary_10_2174_1389450121666200312105908 crossref_primary_10_1016_j_molonc_2012_02_003 crossref_primary_10_2217_ahe_13_25 crossref_primary_10_1007_s10549_013_2622_y crossref_primary_10_1038_s41416_020_01216_6 crossref_primary_10_1038_s41598_017_11817_6 crossref_primary_10_1111_his_12278 crossref_primary_10_1186_s12885_015_1283_0 crossref_primary_10_3389_fphar_2020_632079 crossref_primary_10_1111_his_13523 crossref_primary_10_1111_j_1349_7006_2011_02151_x crossref_primary_10_1517_14728222_2012_655725 crossref_primary_10_2217_bmm_2018_0322 crossref_primary_10_1016_j_molonc_2014_03_008 crossref_primary_10_1016_j_breast_2016_06_019 crossref_primary_10_1186_s13058_018_0946_6 crossref_primary_10_3109_10520295_2014_978893 crossref_primary_10_1155_2012_873570 crossref_primary_10_1038_nrd_2018_71 crossref_primary_10_5858_arpa_2014_0599_OA crossref_primary_10_1016_j_critrevonc_2022_103897 crossref_primary_10_1016_j_critrevonc_2020_102964 crossref_primary_10_1038_s42003_018_0239_8 crossref_primary_10_1007_s00535_016_1178_0 crossref_primary_10_1038_bjc_2014_530 crossref_primary_10_3892_ol_2015_3486 crossref_primary_10_3389_fchem_2020_564809 crossref_primary_10_1038_modpathol_2013_88 crossref_primary_10_1093_jnci_djr484 crossref_primary_10_1111_his_13334 crossref_primary_10_1038_bjc_2011_228 crossref_primary_10_1200_JCO_2012_42_8896 crossref_primary_10_1007_s10549_015_3483_3 crossref_primary_10_5306_wjco_v5_i5_883 crossref_primary_10_1371_journal_pone_0226634 |
Cites_doi | 10.1093/jnci/djj052 10.1002/cncr.23193 10.1038/415530a 10.1016/S0140-6736(05)66544-0 10.1111/j.1365-2559.2009.03429.x 10.1038/35021093 10.1056/NEJMoa041588 10.1093/jnci/dji427 10.1309/AJCPLN78ZQXEMNMA 10.1200/JCO.2006.05.6564 10.1056/NEJMoa040331 10.1200/JCO.2008.19.5594 10.1158/1078-0432.CCR-08-0647 10.1016/j.ejca.2007.11.012 10.1016/S1040-8428(99)00034-7 10.1038/sj.bjc.6605231 10.1158/1078-0432.CCR-07-4756 10.1186/bcr1119 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2010 BioMed Central Ltd. Copyright National Library of Medicine - MEDLINE Abstracts 2010 Copyright ©2010 Bartlett et al.; licensee BioMed Central Ltd. 2010 Bartlett et al.; licensee BioMed Central Ltd. |
Copyright_xml | – notice: COPYRIGHT 2010 BioMed Central Ltd. – notice: Copyright National Library of Medicine - MEDLINE Abstracts 2010 – notice: Copyright ©2010 Bartlett et al.; licensee BioMed Central Ltd. 2010 Bartlett et al.; licensee BioMed Central Ltd. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION K9. 7X8 5PM |
DOI | 10.1186/bcr2604 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1465-542X |
EndPage | R47 |
ExternalDocumentID | oai_biomedcentral_com_bcr2604 2155585271 A480605295 10_1186_bcr2604 20615243 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 04C 0R~ 23N 2VQ 2WC 3V. 4.4 53G 5GY 5VS 6J9 7X7 8FI 8FJ AAFWJ AAJSJ AAWTL ABUWG ACGFO ACGFS ACJQM ACMJI ACPRK ACRMQ ADBBV ADFRT ADINQ ADUKV AENEX AFKRA AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BMSDO BPHCQ BVXVI C1A C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF EIHBH EJD F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE HZ~ IAO ICW IHR INH INR ITC KQ8 LGEZI LOTEE NADUK NPM NXXTH O5R O5S O9- OK1 P2P PGMZT PIMPY PQQKQ PROAC RBZ ROL RPM RSV SBL SOJ TR2 U2A UKHRP WOQ AAYXX CITATION K9. 7X8 ABVAZ AFGXO AFNRJ AFPKN ZA5 5PM |
ID | FETCH-LOGICAL-b509t-4875ca2c01761c274b463ee5c2cf2e7bc194a24ce3b4a021b9879450d67de1173 |
IEDL.DBID | RPM |
ISSN | 1465-542X 1465-5411 |
IngestDate | Tue Sep 17 21:08:49 EDT 2024 Wed May 22 07:10:40 EDT 2024 Fri Oct 25 01:37:26 EDT 2024 Thu Oct 10 18:44:55 EDT 2024 Tue Nov 19 21:20:15 EST 2024 Tue Nov 12 22:47:48 EST 2024 Fri Nov 22 01:41:03 EST 2024 Tue Oct 15 23:38:00 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b509t-4875ca2c01761c274b463ee5c2cf2e7bc194a24ce3b4a021b9879450d67de1173 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949634/ |
PMID | 20615243 |
PQID | 756745445 |
PQPubID | 42565 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2949634 biomedcentral_primary_oai_biomedcentral_com_bcr2604 proquest_miscellaneous_756668901 proquest_journals_756745445 gale_infotracmisc_A480605295 gale_infotracacademiconefile_A480605295 crossref_primary_10_1186_bcr2604 pubmed_primary_20615243 |
PublicationCentury | 2000 |
PublicationDate | 2010-01-01 |
PublicationDateYYYYMMDD | 2010-01-01 |
PublicationDate_xml | – month: 01 year: 2010 text: 2010-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Breast cancer research : BCR |
PublicationTitleAlternate | Breast Cancer Res |
PublicationYear | 2010 |
Publisher | BioMed Central Ltd National Library of Medicine - MEDLINE Abstracts BioMed Central |
Publisher_xml | – name: BioMed Central Ltd – name: National Library of Medicine - MEDLINE Abstracts – name: BioMed Central |
References | 18927301 - Clin Cancer Res. 2008 Oct 15;14(20):6602-9 18698033 - Clin Cancer Res. 2008 Aug 15;14(16):5158-65 19672259 - Br J Cancer. 2009 Sep 15;101(6):875-8 19139426 - J Clin Oncol. 2009 Feb 20;27(6):840-2 19095573 - Am J Clin Pathol. 2009 Jan;131(1):106-11 18072256 - Cancer. 2008 Feb 1;112(3 Suppl):700-9 16478745 - J Natl Cancer Inst. 2006 Feb 15;98(4):262-72 12670887 - Cancer Res. 2003 Apr 1;63(7):1445-8 15014181 - N Engl J Med. 2004 Mar 11;350(11):1081-92 16809728 - J Clin Oncol. 2006 Jul 1;24(19):3039-47 19845790 - Histopathology. 2009 Dec;55(6):724-31 15894097 - Lancet. 2005 May 14-20;365(9472):1687-717 16368942 - J Natl Cancer Inst. 2005 Dec 21;97(24):1808-15 11823860 - Nature. 2002 Jan 31;415(6871):530-6 10963602 - Nature. 2000 Aug 17;406(6797):747-52 15591335 - N Engl J Med. 2004 Dec 30;351(27):2817-26 10532196 - Crit Rev Oncol Hematol. 1999 Aug;31(3):209-23 CM Perou (2565_CR7) 2000; 406 S Paik (2565_CR14) 2004; 351 BZ Ring (2565_CR15) 2006; 24 RL Camp (2565_CR19) 2003; 63 S Pancholi (2565_CR2) 2005; 7 L Hughes-Davies (2565_CR4) 2009; 101 PM Ravdin (2565_CR9) 2003; 82 A McCabe (2565_CR18) 2005; 97 JMS Bartlett (2565_CR21) 2009; 131 C Desmedt (2565_CR10) 2008; 44 C Desmedt (2565_CR11) 2008; 14 C Sotiriou (2565_CR12) 2006; 98 RC Coombes (2565_CR3) 2004; 350 DT Ross (2565_CR16) 2008; 14 B Seruga (2565_CR5) 2009; 27 JMS Bartlett (2565_CR20) 2009; 69 AU Buzdar (2565_CR6) 2008; 112 JS Thomas (2565_CR17) 2009; 55 LJ van't Veer (2565_CR13) 2002; 415 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2565_CR1) 2005; 365 CW Elston (2565_CR8) 1999; 31 |
References_xml | – volume: 98 start-page: 262 year: 2006 ident: 2565_CR12 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djj052 contributor: fullname: C Sotiriou – volume: 112 start-page: 700 year: 2008 ident: 2565_CR6 publication-title: Cancer doi: 10.1002/cncr.23193 contributor: fullname: AU Buzdar – volume: 415 start-page: 530 year: 2002 ident: 2565_CR13 publication-title: Nature doi: 10.1038/415530a contributor: fullname: LJ van't Veer – volume: 365 start-page: 1687 year: 2005 ident: 2565_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(05)66544-0 contributor: fullname: Early Breast Cancer Trialists' Collaborative Group (EBCTCG) – volume: 55 start-page: 724 year: 2009 ident: 2565_CR17 publication-title: Histopathology doi: 10.1111/j.1365-2559.2009.03429.x contributor: fullname: JS Thomas – volume: 406 start-page: 747 year: 2000 ident: 2565_CR7 publication-title: Nature doi: 10.1038/35021093 contributor: fullname: CM Perou – volume: 351 start-page: 2817 year: 2004 ident: 2565_CR14 publication-title: N Engl J Med doi: 10.1056/NEJMoa041588 contributor: fullname: S Paik – volume: 82 start-page: 321 year: 2003 ident: 2565_CR9 publication-title: Breast Cancer Res Treat contributor: fullname: PM Ravdin – volume: 63 start-page: 1445 year: 2003 ident: 2565_CR19 publication-title: Cancer Res contributor: fullname: RL Camp – volume: 97 start-page: 1808 year: 2005 ident: 2565_CR18 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji427 contributor: fullname: A McCabe – volume: 131 start-page: 106 year: 2009 ident: 2565_CR21 publication-title: Am J Clin Pathol doi: 10.1309/AJCPLN78ZQXEMNMA contributor: fullname: JMS Bartlett – volume: 24 start-page: 3039 year: 2006 ident: 2565_CR15 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.05.6564 contributor: fullname: BZ Ring – volume: 350 start-page: 1081 year: 2004 ident: 2565_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMoa040331 contributor: fullname: RC Coombes – volume: 27 start-page: 840 year: 2009 ident: 2565_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.19.5594 contributor: fullname: B Seruga – volume: 14 start-page: 6602 year: 2008 ident: 2565_CR16 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0647 contributor: fullname: DT Ross – volume: 44 start-page: 326 year: 2008 ident: 2565_CR10 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2007.11.012 contributor: fullname: C Desmedt – volume: 69 start-page: 206S year: 2009 ident: 2565_CR20 publication-title: Cancer Res contributor: fullname: JMS Bartlett – volume: 31 start-page: 209 year: 1999 ident: 2565_CR8 publication-title: Crit Rev Oncol Hematol doi: 10.1016/S1040-8428(99)00034-7 contributor: fullname: CW Elston – volume: 101 start-page: 875 year: 2009 ident: 2565_CR4 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605231 contributor: fullname: L Hughes-Davies – volume: 14 start-page: 5158 year: 2008 ident: 2565_CR11 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-4756 contributor: fullname: C Desmedt – volume: 7 start-page: P2.08 year: 2005 ident: 2565_CR2 publication-title: Breast Cancer Res doi: 10.1186/bcr1119 contributor: fullname: S Pancholi |
SSID | ssj0017858 |
Score | 2.3028429 |
Snippet | Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher... Introduction Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for... Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected... INTRODUCTIONPatients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients... INTRODUCTION: Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for... |
SourceID | pubmedcentral biomedcentral proquest gale crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | R47 |
SubjectTerms | Antineoplastic Agents, Hormonal - therapeutic use Biomarkers, Tumor - metabolism Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cancer patients Cancer research Carcinoembryonic Antigen - metabolism Care and treatment Cell Cycle Proteins - metabolism Chemotherapy Chemotherapy, Adjuvant Diagnostic Tests, Routine - methods Disease-Free Survival Estrogens Female GPI-Linked Proteins - metabolism Health aspects Humans Immunohistochemistry Intracellular Signaling Peptides and Proteins - metabolism Large Neutral Amino Acid-Transporter 1 - metabolism Lumpectomy Middle Aged Multivariate Analysis Neoplasm Recurrence, Local Postmenopausal women Prognosis Receptors, Estrogen - metabolism Recurrence (Disease) Reproducibility of Results Risk Assessment - methods Risk Factors Sensitivity and Specificity Tamoxifen Tamoxifen - therapeutic use Tumor proteins Tumor Suppressor Protein p53 - metabolism |
SummonAdditionalLinks | – databaseName: BioMedCentral Open Access* dbid: RBZ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Pa90wDBddB2OX0bX7k7YbGoztFBY7_pMc38ZKGXSHsULZJdiOQwddMl7Tw_tS_RD9ZJWd9PW57LRLCEgCx7IiyZZ-BnjvZQBxKXSuGe9yIb3OSc0tvRU116Y1ysZqi-_q-FR8O5NnW_Du3yf4rFKfrFtSzC0ewWPKFMqQX_34_Gt9UKCreAUn2bvMpWBs6ovdFHzQyX6ROKCHv-ENP5TWSG44naMdeDZHi7iY1Psctny_C3uLnjLlPyv8gLF-M26M78KTk_mYfA_OTwwtr4iIe3ON5hINjsNwQQ-cYHK7FdpQjT6iC1pf4gyvSpwjhmpzHDpchq342AyIUzMj-r4dXGgXxKlta_UCTo--_vxynM9XKuSWJn_MQ3riDHc0cYo5ykitUKX30nHXca-tY7UwXDhfWmHI_du6IoOVRat06xnT5UvY7ofevwZUuvZSs7b0IYWTunYV6ypljG2VcmWRQZnMe_N3gs9oAqB1SiHbamZtZYB32lkLxDylUvcsH4PWmmCBJO7M3EhAwwpYVs1CVIWKB5gZHCacZDkuIR_c6b2ZLfey0VJpERCKaCRrahAMxWi9H64ii1IVBVIZvJoWyXqoPESIXJQZ6GT5JB-fUvrf5xHVm9eCrETs_9e0HcDTqawh7A0dwva4vPJvKFoa7dtoL7cLPxfc priority: 500 providerName: BioMedCentral |
Title | Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/20615243 https://www.proquest.com/docview/756745445 https://search.proquest.com/docview/756668901 http://dx.doi.org/10.1186/bcr2604 https://pubmed.ncbi.nlm.nih.gov/PMC2949634 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6SHEovpU36cJMGHUp7ctYPPezjNjSEwIZSGgi9GEmWSWDXDhvnsH-qP6K_rDOyvY1yzMUYJBnZM-OZkb75BPDZCSJxSVSs0qyJuXAqRjHXeJeUmdK1lsajLS7l-RW_uBbXOyCmWhgP2rfm9qRdrk7a2xuPrbxb2dmEE5v9WJxmJccH8tku7KL7nVL0cetAFf5QTvwDiFjwNB0qZTGOljNj1xi-01E8GXnyjEp1gjL3ZeCdnv6jHzmpEED5yCOdvYZXYyjJ5sOU38COa_fhYN5iGr3asC_Mgzv9qvk-vFiMe-gHcLPQqHueLvfvH6bvmWZ91y3xwgYO3WbDDEHVe2ZJJdZs5F7Fnj0jKDrrGramdXpfKciGSkfm2rqzVEvIhpquzVu4Ovv-6_Q8Hs9biA1Kpo8pd7E6s_gNZWoxXTVc5s4Jm9kmc8rYtOQ649blhmuMDUxZoDWLpJaqdmmq8new13at-wBMqtIJlda5o_xOqNIWaVNIrU0tpc2TCPLgu1d3A7dGRWzXYQsaXjUKLgI2SWc7wCcxhfzf5StJrSLzxOFWj1UGOC0iuqrmvEik392M4CjoiWZlg-bDSe7VaNb3lRJScaIvwplsW2kgIdVa1z34LlIWGGVF8H5Qku1UJ6WLQAXqE7x82IIW4Cm_R43_-OyRh_BywD3Q4tER7PXrB_cJw6neHPtlCLz-_Pb72JvSP33BJJk |
link.rule.ids | 108,230,314,727,780,784,864,885,24937,27924,27925,53791,53793,75811,75812 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RKrW9oBb6CI_Wh6o9hY0TP5LjChUtLYt6AIlbZDuOQNpN0BIO-6f6I_hljJ1ki3vsZbWS7ZU3MxPP2N_3GeCr5U7EJZGxpGkdM25ljGau8FtSpFJVSmiPtrgQsyv285pfbwEfuTAetG_07XGzWB43tzceW3m3NJMRJzb5PT9JC4Y_yCYv4CXPZEHHIn04PJC5v5YT3wE85ozSniuLmbSYaLPCBN5dxpO6tTx1ZJ2A6L4I1qd_39LPlqkQQvlsTTp9CztDMkmm_aTfwZZtdmFv2mAhvVyTb8TDO_2--S68mg-n6HtwM1fofV4w9_EPUfdEka5tF_hBehXdek20A6t3xDinWJFBfRV7dsSB0Ulbk5XbqfdcQdJzHYltqtY4NiHpWV3r93B1-uPyZBYPNy7EGm3Txa56MSo1-AwFNViwaiYya7lJTZ1aqQ0tmEqZsZlmCrMDXeQYzzyphKwspTL7ANtN29hPQIQsLJe0yqyr8LgsTE7rXCilKyFMlkSQBc-9vOvVNUqndx22YOiVg-EiIKN1NgN8GZOLv12-O6uVLkBxuFEDzwCn5aSuyinLE-HPNyM4DHpiYJmg-WC0ezkE9n0puZDMCRjhTDatbqDDqjW2ffBdhMgxz4rgY-8km6mOTheBDNwn-PNhC8aAF_0efH7_v0d-gdezy_l5eX528esA3vQoCLeVdAjb3erBHmFy1enPPpSeADTUJeo |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELYoSKiXqoW2pFDqQ9WeQl5-JMcV7Yo-FnEoErfIdhyBtJuslnDYP8WP4Jd1xkm26x65RJFsR45nxp6xv_lMyGfLkcQllqFM0jpk3MoQxFzBW1ykUlVKaIe2uBQX1-znDb_ZuurLgfaNvjtr5ouz5u7WYSuXCxONOLHoanaeFgw-yKJlVUcvyB7PQMnGQH04QJC5u5oT5gEecpYkfb4seNMi0mYFTjxeyJPiep5iwo6X7D731qj_Z-qtpcqHUW6tS9PX5NXgUNJJ3_E3ZMc2B-Rw0kAwvVjTL9RBPN3e-QHZnw0n6YfkdqZAAx1p7tMjVfdU0a5t5_CgPZNuvaYaAesdNagYKzowsELNjiIgnbY1XeFuvcsXpH2-I7VN1RrMKKR9Ztf6Lbmefv9zfhEOty6EGuTThRjBGJUaGEORGAhaNROZtdykpk6t1CYpmEqZsZlmCjwEXeRg0zyuhKxsksjsHdlt2sYeESpkYblMqsxilMdlYfKkzoVSuhLCZHFAMm_cy2XPsFEi57VfAuZXDoILCB2ls2ngQplc_KvyFaVWopFCc6OGXAPoFtJdlROWx8KdcQbkxKsJxmW84uNR7uVg3Pel5EIyJDGCnmxKsSHi1RrbPrgqQuTgawXkfa8km66OShcQ6amP9_N-CdiBI_4e9P7Ds1t-IvtX36bl7x-Xv47Jyx4IgbtJJ2S3Wz3Yj-BfdfrUWdJfUTsm_Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mammostrat%C2%AEas+a+tool+to+stratify+breast+cancer+patients+at+risk+of+recurrence+during+endocrine+therapy&rft.jtitle=Breast+cancer+research+%3A+BCR&rft.au=Bartlett%2C+John+MS&rft.au=Thomas%2C+Jeremy&rft.au=Ross%2C+Douglas+T&rft.au=Seitz%2C+Robert+S&rft.date=2010-01-01&rft.issn=1465-542X&rft.eissn=1465-542X&rft.volume=12&rft.issue=4&rft_id=info:doi/10.1186%2Fbcr2604&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_bcr2604 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-542X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-542X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-542X&client=summon |